Breaking News

Financial Report: AMRI  

Decline in royalties impacts results

Related CONTENT

05.06.14

AMRI  

1Q Revenues: $59.3 million (flat)

1Q Earnings: $3.5 million (-46%)

Comments: Contract revenue was $51.0 million in the quarter, up 10%. Royalties were $8.3 million, down 36% due to generic competition for Allegra in Japan. Discovery Services and Development / Small Scale Manufacturing ( DDS ) contract revenue for the first quarter was $19.5 million, a decrease of 3%. Decreases in Discovery revenues were partially offset by increases in Development/Small Scale Manufacturing. Large Scale Manufacturing contract revenue was $31.5 million, up 19%.

Related Searches

Suggested For You

GeneQuine, Exothera Enter Gene Therapy Partnership

GeneQuine, Exothera Enter Gene Therapy Partnership

GeneQuine Contracts Exothera to Support the Development of Its Osteoarthritis Gene Therapy

GeneQuine Contracts Exothera to Support the Development of Its Osteoarthritis Gene Therapy

Partnering with a CDMO for Orphan Drug Development

Partnering with a CDMO for Orphan Drug Development

Global Outsourcing Trends

Global Outsourcing Trends

PBS Biotech Scales-Up Manufacturing Solutions for Cell Therapies

PBS Biotech Scales-Up Manufacturing Solutions for Cell Therapies

Curia to Expand U.S. Commercial Manufacturing Capability

Curia to Expand U.S. Commercial Manufacturing Capability

Bora Names Sally Langa Global SVP Sales and Marketing

Bora Names Sally Langa Global SVP Sales and Marketing

Generic APIs Portfolio

Generic APIs Portfolio

DisperSol, Catalent Enter Manufacturing Collaboration

DisperSol, Catalent Enter Manufacturing Collaboration

Abzena, BioXpress Therapeutics Enter Biosimilar Tie-up

Abzena, BioXpress Therapeutics Enter Biosimilar Tie-up

Catalent Biologics Launches GPEx Lightning Cell Line Expression Technology

Catalent Biologics Launches GPEx Lightning Cell Line Expression Technology

Vibalogics Advances Growth with Leadership Hires

Vibalogics Advances Growth with Leadership Hires

Curia to Acquire US-based LakePharma

Curia to Acquire US-based LakePharma

Curia to Acquire Integrity Bio

Curia to Acquire Integrity Bio

Related Breaking News

Breaking News

FourKites and Accenture Share Global Supply Chain Insights for the Pharmaceutical Industry

Pharma executives cite supply chain visibility as critical solution to alleviating product loss and security concerns.
12.07.21
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News | Scale-up/Technology Transfer

BrainStorm, Catalent Complete Tech Transfer for NurOwn

Autologous cell therapy for the treatment of ALS and PMS will be manufactured at Catalent’s 32,000 sq.-ft. cell therapy manufacturing facility in Houston.
12.07.21
Breaking News | Drug Discovery

Metrion Biosciences Enhances Ion Channel Drug Discovery Service Capabilities

Appoints Dr. Gary Clark to lead the expanded services and cell biology capabilities.
12.07.21
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News

EMA Expands Authorization for Roche’s Actemra/RoActemra in COVID

An accelerated assessment by the EMA’s CHMP reviewed results from four studies of Actemra/RoActemra in over 5,500 patients with severe or critical COVID-19.
12.07.21
Breaking News | Industry News

Roquette Invests $25M in U.S. Pharmaceutical Innovation Center

New 23,000 sq.-ft. facility will house an Applied Sciences facility for the research of excipients for oral dosage forms, drug delivery systems, and APIs.
12.07.21
Breaking News | Trials & Filings

Lilly's Bamlanivimab and Etesevimab Gain EUA for Pediatric Use

Expanded authorization based on safety and efficacy in phase 2/3 BLAZE-1 trial in mild to moderate COVID-19 and high risk patients.
12.06.21
Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery | Information Technology

Recursion, Bayer Expand Strategic Fibrosis Alliance

To leverage Recursion's inferential search capabilities based on maps of human cellular biology to accelerate work in fibrotic disease.
12.06.21
Breaking News | Promotions & Moves

Biohaven Appoints Chairman and CFO

Vlad Coric to serve as Chairman and Matthew Buten as Chief Financial Officer.
12.06.21
Breaking News | Drug Development

Astellas Pharma and Dyno Therapeutics Sign Option and License Agreement

Will collaborate to develop next-gen AAV gene therapy vectors for skeletal and cardiac muscle.
12.02.21
Breaking News | Industry News | Vials

SCHOTT Continues to Expand U.S. Presence

Setting a strategic portfolio in the U.S. aims to capitalize on the world’s largest economy and capacity for innovation.
12.02.21
Breaking News | Clinical Trials

Sotio Biotech Secures Funding to Expand & Advance Its Clinical Pipeline

Proceeds will be used to conduct two phase 2 studies with SOT101, including a checkpoint inhibitor combination trial.
12.02.21
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News

FUJIFILM Diosynth Biotechnologies Invests £400M in UK Bio-Mfg. Site

Expansion will more than double the site’s development and manufacturing footprint and is expected to create as many as 350 highly-skilled jobs in Teesside.
12.02.21
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News

CordenPharma Expands Specialty Lipids Production in Chenôve

Invests in Supercritical Fluid Chromatography technology for compound separation, an efficient and cost-effective process for purifying lipids.
12.02.21
Breaking News

Fujifilm Irvine Scientific to Establish New Innovation & Collaboration Center in China

Construction has begun in Suzhou and is planned for completion by March, 2022.
12.01.21
Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Drug Development | Formulation Development | Industry News

Adare Pharma Solutions Acquires Frontida BioPharm

Expands CDMO offerings to include new capabilities such as high potency compound handling and packaging services.
12.01.21